Citius Oncology (CTOR) Assets (2021 - 2026)

Citius Oncology (CTOR) has reported Assets for 6 consecutive years, with $112.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets rose 22.23% year-over-year to $112.1 million in Q2 2026; TTM through Jun 2026 was $112.1 million, a 22.23% increase from a year earlier, with the FY2025 full-year figure at $100.9 million, up 19.64% from the prior year.
• Assets was $112.1 million for Q2 2026 at Citius Oncology, up from $100.7 million in the prior quarter.
• Over five years, Assets peaked at $112.1 million in Q2 2026 and troughed at $256745.0 in Q3 2022.
• A 5-year average of $75.4 million and a median of $78.5 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets jumped 53838.68% in 2022 and fell 29.57% in 2024, its largest moves.
• Over 5 years, Assets stood at $68.2 million in 2022, then grew by 6.5% to $72.6 million in 2023, then rose by 24.59% to $90.5 million in 2024, then increased by 21.54% to $110.0 million in 2025, then gained by 1.93% to $112.1 million in 2026.
• The last three Assets figures came in at $112.1 million (Q2 2026), $100.7 million (Q1 2026), and $110.0 million (Q4 2025), per Business Quant data.